Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.

Nomoto H, Furusawa S, Yokoyama H, Suzuki Y, Izumihara R, Oe Y, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Kurihara Y, Nakamura A, Atsumi T

The Journal of clinical endocrinology and metabolism1 Feb 2025Cited by 4 (Europe PMC)

PMID38695547DOI10.1210/clinem/dgae213PepBankPUB-38695547

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from DPP-4 inhibitors to oral semaglutide raised HOMA2-beta more than continuing the DPP-4 inhibitor (+10.4 vs +0.6).
In plain wordsIn adults with type 2 diabetes, switching to oral semaglutide improved beta-cell function scores more than staying on a DPP-4 inhibitor.
Peptide
Semaglutide
Outcome
IncreaseHOMA2-beta change
Study
n = 146
Comparator
DPP-4 inhibitor continuation
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 24 weeksAs given in this study (human).
Measurements
HOMA2-beta change
10.4 points
semaglutide group
HOMA2-beta change
0.6 points
DPP-4i group
Source sentences
Summary
Regarding indices for β-cell function, changes in HOMA2-β as well as DI, reflecting the ability of β-cells to compensate for insulin resistance, were significantly higher in the semaglutide group compared with the DPP-4i group (mean change, +10.4 vs +0.6 in HOMA2-β [P = .001] and +0.09 vs 0.0 in DI [P < .001]).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed.
Summary · context
Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted.
Report a problemFND-3869554701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from DPP-4 inhibitors to oral semaglutide raised the disposition index more than continuing the DPP-4 inhibitor (+0.09 vs 0.0).
In plain wordsIn adults with type 2 diabetes, switching to oral semaglutide improved beta-cell compensation more than staying on a DPP-4 inhibitor.
Peptide
Semaglutide
Outcome
IncreaseDisposition index change
Study
n = 146
Comparator
DPP-4 inhibitor continuation
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 24 weeksAs given in this study (human).
Measurements
Disposition index change
0.09 units
semaglutide group
Disposition index change
0 units
DPP-4i group
Source sentences
Summary
Regarding indices for β-cell function, changes in HOMA2-β as well as DI, reflecting the ability of β-cells to compensate for insulin resistance, were significantly higher in the semaglutide group compared with the DPP-4i group (mean change, +10.4 vs +0.6 in HOMA2-β [P = .001] and +0.09 vs 0.0 in DI [P < .001]).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed.
Summary · context
Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted.
Report a problemFND-3869554702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes switched to oral semaglutide, glycemic control improved after 24 weeks.
In plain wordsIn adults with type 2 diabetes switched to oral semaglutide, blood sugar control improved after 24 weeks.
Peptide
Semaglutide
Outcome
Not applicableGlycemic control after 24 weeks
Study
n = 69
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
In the semaglutide group, glycemic control, liver enzyme deviations, and lipid profiles improved after 24 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed.
Summary · context
Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted.
Report a problemFND-3869554703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes switched to oral semaglutide, liver enzyme deviations improved after 24 weeks.
In plain wordsIn adults with type 2 diabetes switched to oral semaglutide, abnormal liver enzyme results improved after 24 weeks.
Peptide
Semaglutide
Outcome
Not applicableLiver enzyme deviations after 24 weeks
Study
n = 69
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
In the semaglutide group, glycemic control, liver enzyme deviations, and lipid profiles improved after 24 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed.
Summary · context
Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted.
Report a problemFND-3869554704
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes switched to oral semaglutide, lipid profiles improved after 24 weeks.
In plain wordsIn adults with type 2 diabetes switched to oral semaglutide, blood fat levels improved after 24 weeks.
Peptide
Semaglutide
Outcome
Not applicableLipid profiles after 24 weeks
Study
n = 69
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
In the semaglutide group, glycemic control, liver enzyme deviations, and lipid profiles improved after 24 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed.
Summary · context
Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted.
Report a problemFND-3869554705
06HumanRandomized controlled trialMechanism
In the semaglutide group, improvement in disposition index correlated significantly with changes in BMI, HbA1c and fatty liver index.
In plain wordsIn people on oral semaglutide, bigger gains in beta-cell compensation were linked to changes in weight, HbA1c and liver fat.
Peptide
Semaglutide
Outcome
Not applicableCorrelates of disposition index improvement
Study
n = 69
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Improvement in DI in the semaglutide group was correlated significantly to changes in body mass index (BMI), HbA1c, and fatty liver index reflecting liver steatosis.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed.
Summary · context
Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted.
Report a problemFND-3869554706
07HumanRandomized controlled trialMechanism
In multiple linear regression, semaglutide dose of 7 mg/day or more, reduction in fatty liver index and metformin nonuse were independently associated with disposition index improvement.
In plain wordsHigher semaglutide dose, a bigger drop in the liver fat index and not taking metformin were each linked to a bigger gain in beta-cell compensation.
Peptide
Semaglutide
Outcome
Not applicableIndependent factors for disposition index improvement
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Multiple linear regression analysis revealed that dose of semaglutide (≥ 7 mg/day), reduction in fatty liver index, and metformin nonuse were independently associated with improvement of DI.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed.
Summary · context
Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted.
Report a problemFND-3869554707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords